Janine Makaronidis1,2,3, Chloe Firman1, Cormac G Magee1,2,3, Jessica Mok1,2,3, Nyaladzi Balogun1,3, Matt Lechner4,5,6, Alisia Carnemolla1,3, Rachel L Batterham7,8,9. 1. UCL Centre for Obesity Research, Division of Medicine, University College London, London, UK. 2. Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospital, London, UK. 3. National Institute of Health Research, UCLH Biomedical Research Centre, London, UK. 4. UCL Cancer Institute, University College London, London, UK. 5. Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, CA, USA. 6. Barts Health NHS Trust, London, UK. 7. UCL Centre for Obesity Research, Division of Medicine, University College London, London, UK. r.batterham@ucl.ac.uk. 8. Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospital, London, UK. r.batterham@ucl.ac.uk. 9. National Institute of Health Research, UCLH Biomedical Research Centre, London, UK. r.batterham@ucl.ac.uk.
Abstract
BACKGROUND: Loss of smell and/or taste are cardinal symptoms of COVID-19. 'Long-COVID', persistence of symptoms, affects around one fifth of people. However, data regarding the clinical resolution of loss of smell and/or taste are lacking. In this study we assess smell and taste loss resolution at 4-6 week follow-up, aim to identify risk factors for persistent smell loss and describe smell loss as a feature of long-COVID in a community cohort in London with known SARS-CoV-2 IgG/IgM antibody status. We also compare subjective and objective smell assessments in a subset of participants. METHODS: Four hundred sixty-seven participants with acute loss of smell and/or taste who had undergone SARS-CoV-2 IgG/IgM antibody testing 4-6 weeks earlier completed a follow-up questionnaire about resolution of their symptoms. A subsample of 50 participants completed an objective olfactory test and results were compared to subjective smell evaluations. RESULTS: People with SARS-CoV-2 antibodies with an acute loss of sense of smell and taste were significantly less likely to recover their sense of smell/taste than people who were seronegative (smell recovery: 57.7% vs. 72.1%, p = 0.027. taste recovery 66.2% vs. 80.3%, p = 0.017). In SARS-CoV-2 positive participants, a higher percentage of male participants reported full resolution of smell loss (72.8% vs. 51.4%; p < 0.001) compared to female participants, who were almost 2.5-times more likely to have ongoing smell loss after 4-6 weeks (OR 2.46, 95%CI 1.47-4.13, p = 0.001). Female participants with SARS-CoV-2 antibodies and unresolved smell loss and unresolved taste loss were significantly older (> 40 years) than those who reported full resolution. Participants who experienced parosmia reported lower smell recovery rates and participants with distorted taste perception lower taste recovery rates. Parosmia had a significant association to unresolved smell loss (OR 2.47, 95%CI 1.54-4.00, p < 0.001). CONCLUSION: Although smell and/or taste loss are often transient manifestations of COVID-19, 42% of participants had ongoing loss of smell, 34% loss of taste and 36% loss of smell and taste at 4-6 weeks follow-up, which constitute symptoms of 'long-COVID'. Females (particularly > 40 years) and people with a distorted perception of their sense of smell/taste are likely to benefit from prioritised early therapeutic interventions. TRIALS REGISTRATION: ClinicalTrials.gov NCT04377815 Date of registration: 23/04/2020.
BACKGROUND: Loss of smell and/or taste are cardinal symptoms of COVID-19. 'Long-COVID', persistence of symptoms, affects around one fifth of people. However, data regarding the clinical resolution of loss of smell and/or taste are lacking. In this study we assess smell and taste loss resolution at 4-6 week follow-up, aim to identify risk factors for persistent smell loss and describe smell loss as a feature of long-COVID in a community cohort in London with known SARS-CoV-2 IgG/IgM antibody status. We also compare subjective and objective smell assessments in a subset of participants. METHODS: Four hundred sixty-seven participants with acute loss of smell and/or taste who had undergone SARS-CoV-2 IgG/IgM antibody testing 4-6 weeks earlier completed a follow-up questionnaire about resolution of their symptoms. A subsample of 50 participants completed an objective olfactory test and results were compared to subjective smell evaluations. RESULTS:People with SARS-CoV-2 antibodies with an acute loss of sense of smell and taste were significantly less likely to recover their sense of smell/taste than people who were seronegative (smell recovery: 57.7% vs. 72.1%, p = 0.027. taste recovery 66.2% vs. 80.3%, p = 0.017). In SARS-CoV-2 positive participants, a higher percentage of male participants reported full resolution of smell loss (72.8% vs. 51.4%; p < 0.001) compared to female participants, who were almost 2.5-times more likely to have ongoing smell loss after 4-6 weeks (OR 2.46, 95%CI 1.47-4.13, p = 0.001). Female participants with SARS-CoV-2 antibodies and unresolved smell loss and unresolved taste loss were significantly older (> 40 years) than those who reported full resolution. Participants who experienced parosmia reported lower smell recovery rates and participants with distorted taste perception lower taste recovery rates. Parosmia had a significant association to unresolved smell loss (OR 2.47, 95%CI 1.54-4.00, p < 0.001). CONCLUSION: Although smell and/or taste loss are often transient manifestations of COVID-19, 42% of participants had ongoing loss of smell, 34% loss of taste and 36% loss of smell and taste at 4-6 weeks follow-up, which constitute symptoms of 'long-COVID'. Females (particularly > 40 years) and people with a distorted perception of their sense of smell/taste are likely to benefit from prioritised early therapeutic interventions. TRIALS REGISTRATION: ClinicalTrials.gov NCT04377815 Date of registration: 23/04/2020.
Authors: David T Liu; Maha Sabha; Michael Damm; Carl Philpott; Anna Oleszkiewicz; Antje Hähner; Thomas Hummel Journal: Laryngoscope Date: 2020-11-19 Impact factor: 3.325
Authors: Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann Journal: Cell Date: 2020-03-05 Impact factor: 41.582
Authors: Á Beltrán-Corbellini; J L Chico-García; J Martínez-Poles; F Rodríguez-Jorge; E Natera-Villalba; J Gómez-Corral; A Gómez-López; E Monreal; P Parra-Díaz; J L Cortés-Cuevas; J C Galán; C Fragola-Arnau; J Porta-Etessam; J Masjuan; A Alonso-Cánovas Journal: Eur J Neurol Date: 2020-05-16 Impact factor: 6.288
Authors: L A Vaira; C Hopkins; M Petrocelli; J R Lechien; C M Chiesa-Estomba; G Salzano; M Cucurullo; F A Salzano; S Saussez; P Boscolo-Rizzo; F Biglioli; G De Riu Journal: J Laryngol Otol Date: 2020-08-12 Impact factor: 1.469
Authors: Mackenzie E Hannum; Riley J Koch; Vicente A Ramirez; Sarah S Marks; Aurora K Toskala; Riley D Herriman; Cailu Lin; Paule V Joseph; Danielle R Reed Journal: Chem Senses Date: 2022-01-01 Impact factor: 3.160
Authors: Mackenzie E Hannum; Riley J Koch; Vicente A Ramirez; Sarah S Marks; Aurora K Toskala; Riley D Herriman; Cailu Lin; Paule V Joseph; Danielle R Reed Journal: medRxiv Date: 2021-10-09
Authors: Mena Said; Thanh Luong; Sophie S Jang; Morgan E Davis; Adam S DeConde; Carol H Yan Journal: Int Forum Allergy Rhinol Date: 2022-01-31 Impact factor: 5.426
Authors: Joseph B Gary; Liam Gallagher; Paule V Joseph; Danielle Reed; David A Gudis; Jonathan B Overdevest Journal: Am J Rhinol Allergy Date: 2022-08-11 Impact factor: 2.300
Authors: Ellen J Thompson; Dylan M Williams; Alex J Walker; Ruth E Mitchell; Claire L Niedzwiedz; Tiffany C Yang; Charlotte F Huggins; Alex S F Kwong; Richard J Silverwood; Giorgio Di Gessa; Ruth C E Bowyer; Kate Northstone; Bo Hou; Michael J Green; Brian Dodgeon; Katie J Doores; Emma L Duncan; Frances M K Williams; Andrew Steptoe; David J Porteous; Rosemary R C McEachan; Laurie Tomlinson; Ben Goldacre; Praveetha Patalay; George B Ploubidis; Srinivasa Vittal Katikireddi; Kate Tilling; Christopher T Rentsch; Nicholas J Timpson; Nishi Chaturvedi; Claire J Steves Journal: Nat Commun Date: 2022-06-28 Impact factor: 17.694